pamidronate has been researched along with Adenocarcinoma in 19 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 9.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 7.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Pamidronate disodium is a second-generation biphosphonate, a group of compounds that are being used increasingly to inhibit bone resorption in disorders that are characterized by excessive bone loss such, as hypercalcemia of malignancy, osteoporosis, and Paget's disease." | 5.29 | Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site. ( Ford, JM; Fuji, T; Fushimi, H; Tanaka, M, 1996) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 5.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 3.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Pamidronate was well tolerated and only grade 1 or 2 toxicities were registered." | 1.35 | Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. ( Mitterer, M; Seeber, A; Spizzo, G, 2009) |
| "Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers." | 1.33 | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. ( Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005) |
| "Hypercalcemia was induced either by sc inoculation of syngeneic colon (C-26) adenocarcinoma cells or by sc injection of high-dose recombinant PTHrP (0." | 1.33 | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. ( Adamu, S; Asuncion, F; Capparelli, C; Dunstan, CR; Geng, Z; Grisanti, M; Kostenuik, PJ; Morony, S; Starnes, C; Tan, HL; Warmington, K; Weimann, B, 2005) |
| "Pamidronate appears to be an effective therapy for HPOA." | 1.30 | The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA). ( Francis, H; Nicklason, F; Speden, D; Ward, J, 1997) |
| "Pamidronate disodium is a second-generation biphosphonate, a group of compounds that are being used increasingly to inhibit bone resorption in disorders that are characterized by excessive bone loss such, as hypercalcemia of malignancy, osteoporosis, and Paget's disease." | 1.29 | Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site. ( Ford, JM; Fuji, T; Fushimi, H; Tanaka, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Maatallah, K | 1 |
| Ben Nessib, D | 1 |
| Labbène, E | 1 |
| Ferjani, H | 1 |
| Bouaziz, M | 1 |
| Kaffel, D | 1 |
| Hamdi, W | 1 |
| Santolaria, T | 1 |
| Robard, M | 1 |
| Léger, A | 1 |
| Catros, V | 1 |
| Bonneville, M | 1 |
| Scotet, E | 1 |
| Spizzo, G | 1 |
| Seeber, A | 1 |
| Mitterer, M | 1 |
| ten Dam, MA | 1 |
| Hilbrands, LB | 1 |
| Wetzels, JF | 1 |
| Lipton, A | 1 |
| Small, E | 1 |
| Saad, F | 1 |
| Gleason, D | 1 |
| Gordon, D | 1 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 1 |
| Reitsma, D | 1 |
| Seaman, J | 1 |
| Burton, DW | 1 |
| Geller, J | 1 |
| Yang, M | 1 |
| Jiang, P | 1 |
| Barken, I | 1 |
| Hastings, RH | 1 |
| Hoffman, RM | 1 |
| Deftos, LJ | 1 |
| Morony, S | 1 |
| Warmington, K | 1 |
| Adamu, S | 1 |
| Asuncion, F | 1 |
| Geng, Z | 1 |
| Grisanti, M | 1 |
| Tan, HL | 1 |
| Capparelli, C | 1 |
| Starnes, C | 1 |
| Weimann, B | 1 |
| Dunstan, CR | 1 |
| Kostenuik, PJ | 1 |
| Hay, KD | 1 |
| Bishop, PA | 1 |
| Issat, T | 1 |
| Nowis, D | 1 |
| Legat, M | 1 |
| Makowski, M | 1 |
| Klejman, MP | 1 |
| Urbanski, J | 1 |
| Skierski, J | 1 |
| Koronkiewicz, M | 1 |
| Stoklosa, T | 1 |
| Brzezinska, A | 1 |
| Bil, J | 1 |
| Gietka, J | 1 |
| Jakóbisiak, M | 1 |
| Golab, J | 1 |
| Sanna, G | 1 |
| Preda, L | 1 |
| Bruschini, R | 1 |
| Cossu Rocca, M | 1 |
| Verri, E | 1 |
| Bellomi, M | 1 |
| Goldhirsch, A | 1 |
| Nole, F | 1 |
| Kristensen, B | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 1 |
| Jensen, MB | 1 |
| Andersen, J | 1 |
| Bjerregaard, B | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| Kamby, C | 1 |
| Lindman, H | 1 |
| Nordenskjöld, B | 1 |
| Bergh, J | 1 |
| Tanaka, M | 1 |
| Fushimi, H | 1 |
| Fuji, T | 1 |
| Ford, JM | 1 |
| Speden, D | 1 |
| Nicklason, F | 1 |
| Francis, H | 1 |
| Ward, J | 1 |
| Sims, EC | 1 |
| Rogers, PB | 1 |
| Besser, GM | 1 |
| Plowman, PN | 1 |
| Koshida, H | 1 |
| Kametani, T | 1 |
| Masuda, S | 1 |
| Nemoto, R | 1 |
| Sato, S | 1 |
| Nishijima, Y | 1 |
| Miyakawa, I | 1 |
| Koiso, K | 1 |
| Harada, M | 1 |
| Masud, T | 1 |
| Slevin, ML | 1 |
| Heaf, JG | 1 |
| Hansen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pamidronate and Adenocarcinoma
| Article | Year |
|---|---|
Paget's Disease of Bone in Patients under 40 Years: Two case reports and review of the literature.
Topics: Adenocarcinoma; Adult; Alkaline Phosphatase; Female; Humans; Magnetic Resonance Imaging; Male; Ostei | 2021 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
1 trial available for pamidronate and Adenocarcinoma
| Article | Year |
|---|---|
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2008 |
16 other studies available for pamidronate and Adenocarcinoma
| Article | Year |
|---|---|
You're the Flight Surgeon.
Topics: Adenocarcinoma; Adult; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Diphosphonates; Hum | 2017 |
Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Diphosphonates; Drug Administration Schedule; Humans; Imm | 2013 |
Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Ad | 2009 |
Nephrotic syndrome induced by pamidronate.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Huma | 2011 |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Calcium; Carrier | 2005 |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Carrier Proteins; Cell Lin | 2005 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, T | 2006 |
Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Adh | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Dipho | 2008 |
Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Cervical Vertebrae; Diphosphonates; Female; Humans; Middle Aged; Neoplasms, Unknown | 1996 |
The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Fatal Outcome; Female; Humans; | 1997 |
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Di | 1999 |
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude | 1990 |
Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma.
Topics: Adenocarcinoma; Calcium; Diphosphonates; Humans; Male; Middle Aged; Pain Measurement; Pain, Intracta | 1989 |
Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
Topics: Adenocarcinoma; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Lung Neoplasms | 1988 |